February 17, 2021

Blueprint Medicines

Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results

February 16, 2021

bluebird bio

bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)

February 16, 2021

Kala Pharmaceuticals

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

February 16, 2021


Nurix Therapeutics Reports Fourth Quarter And Fiscal Year 2020 Financial Results And Provides A Corporate Update

February 16, 2021

Sesen Bio

Sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for Vicineum™

Load More

Sign up for weekly portfolio news.